Methods	Allocation: random, no further details. Blinding: double, no further details. Duration: six weeks. Design: parallel. Location: not reported.
Participants	Diagnosis: (ICD-10) acute schizophrenia, schizoaffective disorder. N=48. Age: not reported. Gender: not reported. History: duration of illness not reported, age at onset not reported. Setting: inpatient.
Interventions	Olanzapine: dose: not reported, allowed dose range: not reported, mean dose: not reported. N=24. Ziprasidone: dose: not reported, allowed dose range: not reported, mean dose: not reported. N=24
Outcomes	Mental State: PANSS total score. Adverse effects: EPS (akathisia, parkinsonoid, dystonia). Unable to use- EPS (no data).
Notes
Risk of bias
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Random, no further details.
Allocation concealment (selection bias)	Unclear risk	No further details.
Blinding (performance bias and detection bias) Subjective outcomes	Unclear risk	Double, no further details. Whether blinding was successful has not been examined, but the compounds differ quite substantially in side-effects. This can be a problem for blinding
Blinding (performance bias and detection bias) Objective outcomes	Low risk	Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding
Incomplete outcome data (attrition bias) All outcomes	High risk	Data on subjects leaving the study early were not available.
Selective reporting (reporting bias)	High risk	Allowed study medication dose ranges were not indicated. A publication was not available
Other bias	Unclear risk	Insufficient information, although the first author kindly provided us some

Diagnostic tool

DSM III-R and DSM-IV - Diagnostic Statistical Manual version 3 Revised and version 4.

ICD 10 - The International Statistical Classification of Diseases and Related Health Problems.

BMI - Body Mass Index.

Rating Scales:

Global rating scales:

CGI - Clinical Global Impressions.

CGI-S - Clinical Global Impression-Severity.

CGI-I - Clinical Global Impression-Improvement.

Mental state:

BPRS - Brief Psychiatric Rating Scale.

MADRS - Montgomery-Asberg Depression Rating Scale.

MMSE - Wiing Mini Mental State Examination.

PANSS - Positive and Negative Syndrome Scale.

SANS - Scale for the Assessment of Negative Symptoms.

Side effects:

AIMS - Abnormal Involuntary Movement Scale.

BAS - Barnes Akathisia Scale.

BMI - Body mass index.

ESRS - Extrapyramidal Syndrome Rating Scale.

HAS - Hillside Akathisia Scale.

SAS - Simpson-Angus Index - for neurological side effects.

UKU - Udvalg for kliniske ndersogelser Side Effect Rating Scale -side effect rating scale.

Quality of Life:

QoL - Quality of Life Scale.

SWN -Subjective Well-being List.